Table 2.
Routes of administration for prescription stimulant NMU with or without lifetime prescription opioid NMU.
| Characteristics of sample | Prescription stimulant non-oral NMU with prescription opioid NMU (n = 86) | Prescription stimulant non-oral NMU without prescription opioid NMU (n = 139) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Any oral route | 79 | 91.9 | 113 | 81.3 |
| Swallowed whole | 74 | 86.1 | 111 | 79.9 |
| Cut or broke into smaller pieces then swallowed | 27 | 31.4 | 8 | 5.8 |
| Chewed in mouth then swallowed | 18 | 20.9 | 8 | 5.8 |
| Dissolved in liquid then swallowed | 9 | 10.5 | 7 | 5.0 |
| Any Non-oral route | 86 | 100.0 | 139 | 100.0 |
| Snorted | 85 | 98.8 | 138 | 99.3 |
| Smoked | 7 | 8.1 | 1 | 0.7 |
| Injected | 9 | 10.5 | 5 | 3.6 |